Assessment of cytochrome P450 3A4 activity during the menstrual cycle using alfentanil as a noninvasive probe

Anesthesiology

Volumn 87, Issue 1, 1997, Pages 26-35

  Kharasch, Evan D ^a   Russell, Michael ^b   Garton, Kyle ^b   Lentz, Gretchen ^b   Andrew Bowdle, T ^b   Cox, Kathy ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b NONE

Author keywords

Alfentanil, fentanyl, sufentanil; Analgesics, optoid; Anesthetics, intravenous; Enzymes, cytochrome P450 3A4; Menstrual cycle, pharmacokinetics; Variability, women

Indexed keywords

ALFENTANIL; CYTOCHROME P450 ISOENZYME; ESTROGEN; PROGESTERONE;

ADULT; ARTICLE; BOLUS INJECTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DISPOSITION; DRUG ELIMINATION; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN EXPERIMENT; INTRAVENOUS DRUG ADMINISTRATION; MENSTRUAL CYCLE; NORMAL HUMAN; PRIORITY JOURNAL;

ADOLESCENT; ADULT; ALFENTANIL; ANALGESICS, OPIOID; ANESTHETICS, INTRAVENOUS; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; HUMANS; MENSTRUATION; MIXED FUNCTION OXYGENASES;

EID: 0030759151     PISSN: 00033022     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000542-199707000-00005     Document Type: Article

References (54)

1. Wrighton SA, Stevens JC: The human hepatic cytochromes P450 involved in drug metabolism. Crit Rev Toxicol 1992; 22:1-21
2. Gonzalez FJ, Gelboin HV: Role of human cytochromes P450 in the metabolic activation of chemical carcinogens and toxins. Drug Metab Rev 1994; 26:165-83
3. Li AP, Kaminski DL, Rasmussen A: Substrates of human hepatic cytochrome P450 3A4. Toxicology 1995; 104:1-8
4. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP: Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 caucasians, J Pharmacol Exp Ther 1994; 270:414-23
5. Harris RZ, Benet LZ, Schwartz JB: Gender effects in pharmacokinetics and pharmacodynamics. Drugs 1995; 50:222-39
6. Tateishi T, Krivoruk Y, Ueng Y-F, Wood AJJ, Guengerich FP, Wood M: Identification of human liver cytochrome P-450 3A4 as the enzyme responsible for fentanyl and sufentanil N-dealkylation. Anesth Analg 1996; 82:167-72
7. Iribane C, Berthou F, Baird S, Dréano Y, Picart D, Bail JP, Beaune P, Ménez JF: Involvement of cytochrome P450 3A4 enzyme in the N-demethylation of methadone in human liver microsomes. Chem Res Toxicol 1996; 9:365-73
8. Oda Y, Furuichi K, Tanaka K, Hiroi T, Imaoka S, Asada A, Fujimori M, Funae Y: Metabolism of a new local anesthetic, ropivacaine, by human hepatic cytochrome P450. ANESTHESIOLOGY 1995; 82:214- 20
9. Fletcher CV, Acosta EP, Strykowski JM: Gender differences in human pharmacokinetics and pharmacodynamics. J Adolescent Health 1994; 15:619-29
10. Hunt CM, Westerkam WR, Stave GM: Effect of age and gender on the activity of human hepatic CYP3A. Biochem Pharmacol 1992; 44:275-83
11. Schmucker DL, Woodhouse KW, Wang RK, Wynne H, James OF, McManus M, Kremers P: Effects of age and gender on in vitro properties of human liver microsomal monooxygenases. Clin Pharmacol Ther 1990; 48:365-74
12. Lemmens HJM, Burm AGL, Hennis PJ, Gladines MPPR, Bovill JG: Influence of age on the pharmacokinetics of alfentanil - gender dependence. Clin Pharmacokinet 1990; 19:416-22
13. Rubio A, Cox C: Sex, age and alfentanil pharmacokinetics. Clin Pharmacokinet 1991; 21:81-2
14. Wilson K, Oram M, Horth CE, Burnett D: The influence of the menstrual cycle on the metabolism and clearance of methaqualone. Br J Clin Pharmacol 1982; 14:533-9
15. Lane JD, Steege JF, Rupp SL, Kuhn CM: Menstrual cycle effects on caffeine elimination in the human female. Eur J Clin Pharmacol 1992; 43:543-6
16. Schuetz JD, Kauma S, Guzelian PS: Identification of the fetal liver cytochrome CYP3A7 in human endometrium and placenta. J Clin Invest 1993; 92:1018-24
17. Yun C-H, Wood M, Wood AJJ, Guengerich FP: Identification of the pharmacogenetic determinants of alfentanil metabolism: cytochrome P450 3A4. ANESTHESIOLOGY 1992; 77:467-74
18. Kharasch ED, Thummel K: Human alfentanil metabolism by cytochrome P450 3A3/4. An explanation for the interindividual variability in alfentanil clearance? Anesth Analg 1993; 76:1033-9
19. Labroo RB, Thummel KE, Kunze KL, Podoll T, Trager WF, Kharasch ED: Catalytic role of cytochrome P4503A4 in multiple pathways of alfentanil metabolism. Drug Metab Dispos 1995; 23:490-6
20. Kharasch ED, Mautz D, Bowdle TA: Variability in alfentanil pharmacokinetics: the essential role of cytochrome P4503A. ANESTHESIOLOGY 1994; 81:A381
21. Kharasch ED, Russell M, Mautz D, Thummel KE, Kunze KL, Bowdle TA, Cox K: The role of cytochrome P450 3A4 in alfentanil clearance: implications for interindividual variability in disposition and perioperative drug interactions. ANESTHESIOLOGY 1997; 87:36-50
22. Bailey DG, Arnold JMO, Spence JD: Grapefruit juice and drugs: How significant is the interaction? Clin Pharmacokinet 1994; 26:91-8
23. Mautz DM, Labroo RB, Kharasch ED: Determination of alfentanil and noralfentanil in human plasma by gas chromatography-mass spectrometry. J Chromatogr B 1994; 658:149-53
24. Kataria BK, Ved SA, Nicodemus HF, Hoy GR, Lea D, Dubois MY, Mandema JW, Shafer SL: The pharmacokinetics of propofol in children using three different data analysis approaches, ANESTHESIOLOGY 1994; 80:104-22
25. Meuldermans W, Van Peer A, Hendrickx J, Woestenborghs R, Lauwers W, Heykants J, Vanden Bussche G, Van Craeyvelt H, Van Der Aa P: Alfentanil pharmacokinetics and metabolism in humans. ANESTHESIOLOGY 1988; 69:527-34
26. Henthorn TK, Avram MJ, Krejcie TC: Alfentanil clearance is independent of the polymorphic debrisoquin hydroxylase. ANESTHESIOLOGY 1989; 71:635-9
27. Chauvin M, Lebrault C, Levron JC, Duvaldestin P: Pharmacokinetics of alfentanil in chronic renal failure. Anesth Analg 1987; 66:53-6
28. Ferrier C, Marty J, Bouffard Y, Haberer JP, Levron JC, Duvaldestin P: Alfentanil pharmacokinetics in patients with cirrhosis. ANESTHESIOLOGY 1985; 62:480-4
29. Chauvin M, Bonnet F, Montembault C, Levron JC, Viars P: The influence of hepatic plasma flow on alfentanil plasma concentration plateaus achieved with an infusion model in humans. Measurement of alfentanil hepatic extraction coefficient. Anesth Analg 1986; 65:999- 1003
30. Lavrijsen KLM, Van Houdt JMG, Van Dyck DMJ, Hendrickx JJJM, Woestenborghs RJH, Lauwers W, Meuldermans WEG, Heykants JJP: Is the metabolism of alfentanil subject to debrisoquine polymorphism? ANESTHESIOLOGY 1988; 69:535-40
31. Krivoruk Y, Kinirons MT, Wood AJJ, Wood M: Alfentanil disposition in vivo is mediated by CYP3A4 in humans. ANESTHESIOLOGY 1994; 81:A380
32. Thummel KE, Shen DD, Podoll T, Kunze KL, Trager WF, Hartwell P, Raisys V, Marsh CL, McVicar JP, Barr DM, Perkins JD, Carithers RL: Use of midazolam as a human cytochrome P450 3A probe: I. In vitro-in vivo correlations in liver transplant patients. J Pharmacol Exp Ther 1994; 271:549-56
33. Waxman DJ, Ram PA, Notani G, LeBlanc GA, Alberta JA, Morrissey JJ, Sundseth SS: Pituitary regulation of the male-specific steroid 6β-hydroxylase P-450 2a (gene product IIIA2) in adult rat liver. Suppressive influence of growth hormone and thyroxinc acting at a pretranslational level. Mol Endocrinol 1990; 4:447-54
34. Watkins PB, Wrighton SA, Maurel P, Schuetz EG, Mendez-Picon G, Parker GA, Guzelian PS: Identification of an inducible form of cytochrome P-450 in human liver. Proc Natl Acad Sci USA 1985; 82:6310-14
35. Pichard L, Fabre I, Fabre G, Domergue J, Saint Aubert B, Mourad G, Maurel P: Cyclosporin A drug interactions: screening for inducers and inhibitors of cytochrome P-450 (Cyclosporin A oxidase) in primary cultures of human hepatocytes and in liver microsomes. Drug Metab Dispos 1990; 18:595-604
36. Pichard L, Fahre I, Daujat M, Domergue J, Joyeux H, Maurel P: Effect of corticosteroids on the expression of cytochromes P450 and on cyclosporin A oxidase activity in primary cultures of human hepatocytes. Mol Pharmacol 1992; 41:1047-55
37. Schuetz ED, Guzelian PS: Induction of cytochrome P-450 by glucocorticoids in rat liver II. Evidence that glucocorticoids regulate induction of cytochrome P-450 by a nonclassical receptor mechanism. J Biol Chem 1984; 259:2007-12
38. Bruguerolle B, Toumi M, Faraj F, Vervloet D, Razzouk H: Influence of the menstrual cycle on theophylline pharmacokinetics in asthmatics. Eur J Clin Pharmacol 1990; 39:59-61
39. Shavit G, Lerman P, Korczyn AD, Kivity S, Bechar M, Gitter S: Phenytoin pharmacokinetics in catamenial epilepsy. Neurology 1984; 34:959-61
40. Wojcicki J, Gawronska-Szklarz B, Kazimierczyk J, Baskiewicz Z, Raczynski A: Comparative pharmacokinetics of paracetamol in men and women considering follicular and luteal phases. Arzneim Forsch 1979; 29:350-2
41. Maitre PO, Vozeh S, Heykants J, Thomson DA, Stunski DR: Population pharmacokinetics of alfentanil: The average dose-plasma concentration relationship and interindividual variability in patients. ANESTHESIOLOGY 1987; 66:13-16
42. Wood M: Variability of human drug response. ANESTHESIOLOGY 1989; 71:631-4
43. Bovill JG, Sebel PS, Blackburn CL, Heykants J: The pharmacokinetics of alfentanil (R39209): A new opioid analgesic. ANESTHESIOLOGY 1982; 57:439-43
44. Helmers H, Van Peer A, Woestenborghs R, Noorduin H, Hey kants J: Alfentanil kinetics in the elderly. Clin Pharmacol Ther 1984; 36:239-43
45. Shafer A, Sung ML, White PF: Pharmacokinetics and pharmaco- dynamics of alfentanil infusions during general anesthesia. Anesth Analg 1986; 65:1021-8
46. Bower S, Hull CJ: Comparative pharmacokinetics of fentanyl and alfentanil. Br J Anaesth 1982; 54:871-7
47. Henthorn TK, Krejcie TC, Avram MJ: The relationship between alfentanil distribution kinetics and cardiac output. Clin Pharmacol Ther 1992; 52:190-6
48. Watkins PB, Murray SA, Winkelman LG, Heuman DM, Wrighton SA, Guzelian PS: Erythromycin breath test as an assay of glucocorticoid-inducible liver cytochromes P-450: Studies in rats and patients. J Clin Invest 1989; 83:688-97
49. Watkins PB: Noninvasive tests of CYP3A enzymes. Pharmacogenetics 1994; 4:366-8
50. Watkins PB, Turgeon DK, Saenger P, Lown KS, Kolars JC, Hamilton T, Fishman K, Guzelian PS, Voorhees JJ: Comparison of urinary 6-β-cortisol and the erythromycin breath test as measures of hepatic P450IIIA (CYP3A) activity. Clin Pharmacol Ther 1992; 52:265-73
51. Kinirons MT, Oshea D, Downing TE, Fitzwilliam AT, Joellenbeck L, Groopman JD, Wilkinson GR, Wood AJJ: Absence of correlations among 3 putative invivo probes of human cytochrome P4503A activity in young healthy men. Clin Pharmacol Ther 1993; 54:621-9
52. Krivoruk Y, Kinirons MT, Wood AJ, Wood M: Metabolism of cytochrome P4503A substrates in vivo administered by the same route: lack of correlation between alfentanil clearance and erythromycin breath test. Clin Pharmacol Ther 1994; 56:608-14
53. Stein CM, Kinirons MT, Pincus T, Wilkinson GR, Wood AJJ: Comparison of the dapsone recovery ratio and the erythromycin breath test as in vivo probes of CYP3A activity in patients with rheumatoid arthritis receiving cyclosporine. Clin Pharmacol Ther 1996; 59:47-51.
54. Olkkola KT, Backman JT, Neuvonen PJ: Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 1994; 55:481-5